CoChat

Peripheral inflammatory biomarkers define biotypes of bipolar depression

Open access
Lee, Yena, Mansur, Rodrigo B., Brietzke, Elisa, Kapogiannis, Dimitrios, Delgado-Peraza, Francheska, Boutilier, Justin J., Chan, Timothy C. Y., Carmona, Nicole E., Rosenblat, Joshua D., Lee, JungGoo, Maletic, Vladimir, Vinberg, Maj, Suppes, Trisha, Goldstein, Benjamin I., Ravindran, Arun V., Taylor, Valerie H., Chawla, Sahil, Nogueras-Ortiz, Carlos, Cosgrove, Victoria E., Kramer, Nicole E., Ho, Roger, Raison, Charles A., McIntyre, Roger S. · 2021 · Molecular Psychiatry
Cited by 48

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Abstract

We identified biologically relevant moderators of response to tumor necrosis factor (TNF)-α inhibitor, infliximab, among 60 individuals with bipolar depression. Data were derived from a 12-week, randomized, placebo-controlled clinical trial secondarily evaluating the efficacy of infliximab on a measure of anhedonia (i.e., Snaith–Hamilton Pleasure Scale). Three inflammatory biotypes were derived from peripheral cytokine measurements using an iterative, machine learning-based approach. Infliximab-randomized participants classified as biotype 3 exhibited lower baseline concentrations of pro- and anti-inflammatory cytokines and soluble TNF receptor-1 and reported greater pro-hedonic improvements, relative to those classified as biotype 1 or 2. Pretreatment biotypes also moderated changes in neuroinflammatory substrates relevant to infliximab’s hypothesized mechanism of action. Neuronal origin-enriched extracellular vesicle (NEV) protein concentrations were reduced to two factors using principal axis factoring: phosphorylated nuclear factorκB (p-NFκB), Fas-associated death domain (p-FADD), and IκB kinase (p-IKKα/β) and TNF receptor-1 (TNFR1) comprised factor “NEV1,” whereas phosphorylated insulin receptor substrate-1 (p-IRS1), p38 mitogen-activated protein kinase (p-p38), and c-Jun N-terminal kinase (p-JNK) constituted “NEV2”. Among infliximab-randomized subjects classified as biotype 3, NEV1 scores were decreased at weeks 2 and 6 and increased at week 12, relative to baseline, and NEV2 scores increased over time. Decreases in NEV1 scores and increases in NEV2 scores were associated with greater reductions in anhedonic symptoms in our classification and regression tree model ( r 2 = 0.22, RMSE = 0.08). Our findings provide preliminary evidence supporting the hypothesis that the pro-hedonic effects of infliximab require modulation of multiple TNF-α signaling pathways, including NF-κB, IRS1, and MAPK.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41380-021-01051-y

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 15 references

Research works printed but not linked: 45

  1. Fava M, Rush AJ, Wisniewski SR, Nierenberg AA, Alpert JE, McGrath PJ, et al. A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: a STAR*D report. Am J Psychiatry. 2006;163:1161–72. https://doi.org/10.1176/appi.ajp.163.7.1161. · doi:10.1176/appi.ajp.163.7.1161 · Paper page
  2. Trivedi MH, Morris DW, Wisniewski SR, Lesser I, Nierenberg AA, Daly E, et al. Increase in work productivity of depressed individuals with improvement in depressive symptom severity. Am J Psychiatry. 2013;170:633–41. https://doi.org/10.1176/appi.ajp.2012.12020250. · DOI · Paper page
  3. Webb CA, Trivedi MH, Cohen ZD, Dillon DG, Fournier JC, Goer F, et al. Personalized prediction of antidepressant v. placebo response: evidence from the EMBARC study. Psychol Med. 2019;49:1118–27. https://doi.org/10.1017/S0033291718001708. · DOI · Paper page
  4. Lee Y, Ragguett R-M, Mansur RB, Boutilier JJ, Rosenblat JD, Trevizol A, et al. Applications of machine learning algorithms to predict therapeutic outcomes in depression: a meta-analysis and systematic review. J Affect Disord. 2018;241:519–32. https://doi.org/10.1016/j.jad.2018.08.073. · DOI · Paper page
  5. Benedetti F, Poletti S, Hoogenboezem TA, Locatelli C, de Wit H, Wijkhuijs AJM, et al. Higher baseline proinflammatory cytokines mark poor antidepressant response in bipolar disorder. J Clin Psychiatry. 2017;78:e986–93. https://doi.org/10.4088/JCP.16m11310. · DOI · Paper page
  6. Arteaga-Henríquez G, Simon MS, Burger B, Weidinger E, Wijkhuijs A, Arolt V, et al. Low-grade inflammation as a predictor of antidepressant and anti-inflammatory therapy response in MDD patients: a systematic review of the literature in combination with an analysis of experimental data collected in the EU-MOODINFLAME Consortium. Front Psychiatry. 2019;10:458. https://doi.org/10.3389/fpsyt.2019.00458. · DOI · Paper page
  7. Lee Y, Mansur RB, Brietzke E, Carmona NE, Subramaniapillai M, Pan Z, et al. Efficacy of adjunctive infliximab vs. placebo in the treatment of anhedonia in bipolar I/II depression. Brain Behav Immun. 2020. https://doi.org/10.1016/j.bbi.2020.04.063. · DOI
  8. Andersson KME, Wasén C, Juzokaite L, Leifsdottir L, Erlandsson MC, Silfverswärd ST, et al. Inflammation in the hippocampus affects IGF1 receptor signaling and contributes to neurological sequelae in rheumatoid arthritis. Proc Natl Acad Sci USA. 2018;115:E12063–72. https://doi.org/10.1073/pnas.1810553115. · DOI
  9. Nasca C, Dobbin J, Bigio B, Watson K, de Angelis P, Kautz M, et al. Insulin receptor substrate in brain-enriched exosomes in subjects with major depression: on the path of creation of biosignatures of central insulin resistance. Mol Psychiatry. 2020. https://doi.org/10.1038/s41380-020-0804-7. · DOI · Paper page
  10. Millett CE, Harder J, Locascio JJ, Shanahan M, Santone G, Fichorova RN, et al. TNF-α and its soluble receptors mediate the relationship between prior severe mood episodes and cognitive dysfunction in euthymic bipolar disorder. Brain Behav Immun. 2020. https://doi.org/10.1016/j.bbi.2020.04.003. · DOI
  11. Haroon E, Welle JR, Woolwine BJ, Goldsmith DR, Baer W, Patel T, et al. Associations among peripheral and central kynurenine pathway metabolites and inflammation in depression. Neuropsychopharmacology. 2020;45:998–1007. https://doi.org/10.1038/s41386-020-0607-1. · DOI · Paper page
  12. Husain M, Roiser JP. Neuroscience of apathy and anhedonia: a transdiagnostic approach. Nat Rev Neurosci. 2018;19:470–84. https://doi.org/10.1038/s41583-018-0029-9. · DOI · Paper page
  13. Lee Y, Subramaniapillai M, Brietzke E, Mansur RB, Ho RC, Yim SJ, et al. Anti-cytokine agents for anhedonia: targeting inflammation and the immune system to treat dimensional disturbances in depression. Ther Adv Psychopharmacol. 2018;8:337–48. https://doi.org/10.1177/2045125318791944. · DOI · Paper page
  14. Leventhal AM, Chasson GS, Tapia E, Miller EK, Pettit JW. Measuring hedonic capacity in depression: a psychometric analysis of three anhedonia scales. J Clin Psychol. 2006;62:1545–58. https://doi.org/10.1002/jclp.20327. · DOI · Paper page
  15. Kramer NE, Cosgrove VE, Dunlap K, Subramaniapillai M, McIntyre RS, Suppes T. A clinical model for identifying an inflammatory phenotype in mood disorders. J Psychiatr Res. 2019;113:148–58. https://doi.org/10.1016/j.jpsychires.2019.02.005. · DOI
  16. Mustapic M, Eitan E, Werner JK Jr, Berkowitz ST, Lazaropoulos MP, Tran J, et al. Plasma extracellular vesicles enriched for neuronal origin: a potential window into brain pathologic processes. Front Neurosci. 2017;11:278. https://doi.org/10.3389/fnins.2017.00278. · DOI · Paper page
  17. Mullins RJ, Mustapic M, Goetzl EJ, Kapogiannis D. Exosomal biomarkers of brain insulin resistance associated with regional atrophy in Alzheimer’s disease. Hum Brain Mapp. 2017;38:1933–40. https://doi.org/10.1002/hbm.23494. · DOI · Paper page
  18. Athauda D, Gulyani S, Karnati HK, Li Y, Tweedie D, Mustapic M, et al. Utility of neuronal-derived exosomes to examine molecular mechanisms that affect motor function in patients with parkinson disease: a secondary analysis of the exenatide-PD trial. JAMA Neurol. 2019;76:420–9. https://doi.org/10.1001/jamaneurol.2018.4304. · DOI · Paper page
  19. Sáenz-Cuesta M, Arbelaiz A, Oregi A, Irizar H, Osorio-Querejeta I, Muñoz-Culla M, et al. Methods for extracellular vesicles isolation in a hospital setting. Front Immunol. 2015;6:50. https://doi.org/10.3389/fimmu.2015.00050. · DOI · Paper page
  20. Mansur RB, Delgado-Peraza F, Subramaniapillai M, Lee Y, Iacobucci M, Rodrigues N, et al. Extracellular vesicle biomarkers reveal inhibition of neuroinflammation by infliximab in association with antidepressant response in adults with bipolar depression. Cells. 2020;9. https://doi.org/10.3390/cells9040895. · DOI
  21. Breiman L. Classification and regression trees. Boca Raton: Routledge; 2017. · DOI · Paper page
  22. Bergstra J, Bengio Y. Random search for hyper-parameter optimization. J Mach Learn Res. 2012;13:281–305. http://www.jmlr.org/papers/v13/bergstra12a.html.
  23. Shmueli G. To explain or to predict? Stat Sci. 2010;25:289–310. https://projecteuclid.org/euclid.ss/1294167961. · DOI · Paper page
  24. Pedregosa F, Varoquaux G, Gramfort A, Michel V, Thirion B, Grisel O, et al. Scikit-learn: machine learning in python. J Mach Learn Res. 2011;12:2825–30.
  25. Chen G, Bhojani MS, Heaford AC, Chang DC, Laxman B, Thomas DG, et al. Phosphorylated FADD induces NF-kappaB, perturbs cell cycle, and is associated with poor outcome in lung adenocarcinomas. Proc Natl Acad Sci USA. 2005;102:12507–12. https://doi.org/10.1073/pnas.0500397102. · DOI
  26. Lawrence T, Bebien M, Liu GY, Nizet V, Karin M. IKKalpha limits macrophage NF-kappaB activation and contributes to the resolution of inflammation. Nature. 2005;434:1138–43. https://doi.org/10.1038/nature03491. · DOI · Paper page
  27. Christian F, Smith EL, Carmody RJ. The regulation of NF-κB subunits by phosphorylation. Cells. 2016;5. https://doi.org/10.3390/cells5010012. · DOI · Paper page
  28. Block ML, Zecca L, Hong J-S. Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat Rev Neurosci. 2007;8:57–69. https://doi.org/10.1038/nrn2038. · DOI · Paper page
  29. Barger SW, Hörster D, Furukawa K, Goodman Y, Krieglstein J, Mattson MP. Tumor necrosis factors alpha and beta protect neurons against amyloid beta-peptide toxicity: evidence for involvement of a kappa B-binding factor and attenuation of peroxide and Ca2+ accumulation. Proc Natl Acad Sci USA. 1995;92:9328–32. https://doi.org/10.1073/pnas.92.20.9328. · DOI · Paper page
  30. Lügering A, Schmidt M, Lügering N, Pauels HG, Domschke W, Kucharzik T. Infliximab induces apoptosis in monocytes from patients with chronic active Crohn’s disease by using a caspase-dependent pathway. Gastroenterology. 2001;121:1145–57. https://doi.org/10.1053/gast.2001.28702. · DOI · Paper page
  31. Chaudhari U, Romano P, Mulcahy LD, Dooley LT, Baker DG, Gottlieb AB. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet. 2001;357:1842–7. https://doi.org/10.1016/s0140-6736(00)04954-0. · DOI · Paper page
  32. Horiuchi T, Mitoma H, Harashima S-I, Tsukamoto H, Shimoda T. Transmembrane TNF-alpha: structure, function and interaction with anti-TNF agents. Rheumatology. 2010;49:1215–28. https://doi.org/10.1093/rheumatology/keq031. · DOI · Paper page
  33. Mitoma H, Horiuchi T, Hatta N, Tsukamoto H, Harashima S-I, Kikuchi Y, et al. Infliximab induces potent anti-inflammatory responses by outside-to-inside signals through transmembrane TNF-alpha. Gastroenterology. 2005;128:376–92. https://doi.org/10.1053/j.gastro.2004.11.060. · DOI · Paper page
  34. Genovese T, Mazzon E, Crisafulli C, Di Paola R, Muià C, Esposito E, et al. TNF-alpha blockage in a mouse model of SCI: evidence for improved outcome. Shock. 2008;29:32–41. https://doi.org/10.1097/shk.0b013e318059053a. · DOI · Paper page
  35. Hoffmann A, Natoli G, Ghosh G. Transcriptional regulation via the NF-kappaB signaling module. Oncogene. 2006;25:6706–16. https://doi.org/10.1038/sj.onc.1209933. · DOI · Paper page
  36. Lügering A, Lebiedz P, Koch S, Kucharzik T. Apoptosis as a therapeutic tool in IBD? Ann NY Acad Sci. 2006;1072:62–77. https://doi.org/10.1196/annals.1326.013. · DOI · Paper page
  37. Nikolaus S, Raedler A, Kühbacker T, Sfikas N, Fölsch UR, Schreiber S. Mechanisms in failure of infliximab for Crohn’s disease. Lancet. 2000;356:1475–9. https://doi.org/10.1016/s0140-6736(00)02871-3. · DOI
  38. Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, Spiegelman BM. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance. Science. 1996;271:665–8. https://doi.org/10.1126/science.271.5249.665. · DOI · Paper page
  39. Greene MW, Sakaue H, Wang L, Alessi DR, Roth RA. Modulation of insulin-stimulated degradation of human insulin receptor substrate-1 by Serine 312 phosphorylation. J Biol Chem. 2003;278:8199–211. https://doi.org/10.1074/jbc.M209153200. · DOI · Paper page
  40. Stagakis I, Bertsias G, Karvounaris S, Kavousanaki M, Virla D, Raptopoulou A, et al. Anti-tumor necrosis factor therapy improves insulin resistance, beta cell function and insulin signaling in active rheumatoid arthritis patients with high insulin resistance. Arthritis Res Ther. 2012;14:R141 https://doi.org/10.1186/ar3874. · DOI · Paper page
  41. Hançer NJ, Qiu W, Cherella C, Li Y, Copps KD, White MF. Insulin and metabolic stress stimulate multisite serine/threonine phosphorylation of insulin receptor substrate 1 and inhibit tyrosine phosphorylation. J Biol Chem. 2014;289:12467–84. https://doi.org/10.1074/jbc.M114.554162. · DOI · Paper page
  42. Ho RCM, Chua AC, Tran BX, Choo CC, Husain SF, Vu GT, et al. Factors associated with the risk of developing coronary artery disease in medicated patients with major depressive disorder. Int J Environ Res Public Health. 2018;15. https://doi.org/10.3390/ijerph15102073. · DOI
  43. Rosenstiel P, Agnholt J, Kelsen J, Medici V, Waetzig GH, Seegert D, et al. Differential modulation of p38 mitogen activated protein kinase and STAT3 signalling pathways by infliximab and etanercept in intestinal T cells from patients with Crohn’s disease. Gut. 2005;54:314–5. https://www.ncbi.nlm.nih.gov/pubmed/15647208.
  44. Waetzig GH, Seegert D, Rosenstiel P, Nikolaus S, Schreiber S. p38 mitogen-activated protein kinase is activated and linked to TNF-alpha signaling in inflammatory bowel disease. J Immunol. 2002;168:5342–51. https://doi.org/10.4049/jimmunol.168.10.5342. · DOI · Paper page
  45. Waetzig GH, Rosenstiel P, Nikolaus S, Seegert D, Schreiber S. Differential p38 mitogen-activated protein kinase target phosphorylation in responders and nonresponders to infliximab. Gastroenterology. 2003;125:633–4. https://doi.org/10.1016/s0016-5085(03)00979-x. · DOI

Cited by

See all 48

Metadata

Authors
Lee, Y., Mansur, R. B., Brietzke, E., Kapogiannis, D., Delgado-Peraza, F., Boutilier, J. J., Chan, T. C. Y., Carmona, N. E., Rosenblat, J. D., Lee, J., Maletic, V., Vinberg, M., Suppes, T., Goldstein, B. I., Ravindran, A. V., Taylor, V. H., Chawla, S., Nogueras-Ortiz, C., Cosgrove, V. E., Kramer, N. E., Ho, R., Raison, C. A., & McIntyre, R. S.
Venue
Molecular Psychiatry
Published
2021-03-03
Volume
26
Issue
7
Pages
3395-3406
ISSN
  • 1359-4184 (ISSN-L)
  • 1476-5578
OpenAlex
W3134618529
Cited by
48
References
15
FWCI
5.24
Type
journal article
Language
en
Open access
green
Licence
Funders
  • Stanley Medical Research Institute (13T-012)
  • U.S. Department of Health & Human Services | NIH | National Institute on Aging (Z99 AG999999, ZIA AG000975)
  • Stanley Medical Research Institute - 13T-012

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Peripheral inflammatory biomarkers define biotypes of bipolar depression. https://app.cochat.ai/papers/10.1038/s41380-021-01051-y
The paper
Lee, Y., Mansur, R. B., Brietzke, E., Kapogiannis, D., Delgado-Peraza, F., Boutilier, J. J., Chan, T. C. Y., Carmona, N. E., Rosenblat, J. D., Lee, J., Maletic, V., Vinberg, M., Suppes, T., Goldstein, B. I., Ravindran, A. V., Taylor, V. H., Chawla, S., Nogueras-Ortiz, C., Cosgrove, V. E., . . . McIntyre, R. S. (2021). Peripheral inflammatory biomarkers define biotypes of bipolar depression. Molecular Psychiatry. https://doi.org/10.1038/s41380-021-01051-y

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.